Revaprazan
As of the edition of 20 October 2026, Revaprazan is a small molecule: went quiet in 2014; acts on ATP4A and ATP4B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2014
- Kind
- Small molecule
- Registered trials
- 1, 0 stopped early
- Disease areas
- Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 1 |